收稿日期: 2024-03-28
网络出版日期: 2024-08-26
基金资助
湖南省自然科学基金重大项目（揭榜制）(2021JC0003);湖南省临床医疗技术创新引导项目(2021SK53508);湖南省卫生健康高层次人才重大科研专项(R202344)
A new vision of diabetes classification： A shift from clinical manifestation to etiological molecular mechanism
Received date: 2024-03-28
Online published: 2024-08-26
随着医学科技进步和对疾病本质理解的深入，糖尿病的分型正经历着变革，传统基于临床特征和胰岛素依赖性的分类方法逐渐显示出其局限性。近年来，基因组、表观遗传、代谢组学等生物信息技术的应用，以及大数据和机器学习技术在疾病分类中的运用，推动了糖尿病分型向更加精细化和个性化的方向发展。这些新技术揭示了糖尿病复杂的病理生理机制和广泛的异质性，为早期诊断、个性化治疗和预后评估提供了新思路。这一进展不仅对糖尿病的复杂性理解具有重要意义，而且将为患者提供更加精准和有效的治疗方案，标志着糖尿病分型从简单的基于临床表现向基于病因分子机制转变的历史性时刻。
杨舒婷 , 罗说明 , 周智广 . 糖尿病分型新视野——基于临床表现向基于病因分子机制转变[J]. 实用医学杂志, 2024 , 40(16) : 2199 -2205 . DOI: 10.3969/j.issn.1006-5725.2024.16.001
The classification of diabetes is undergoing a significant transformation. As advancements in medical technology and a deeper understanding of its etiology， traditional classification methods based on clinical characteristics and insulin dependency are increasingly revealing their limitations. In recent years， the integration of genomic， epigenetic， and metabolomic technologies， combined with the application of big data analytics and machine learning in disease classification， has propelled diabetes classification towards enhanced precision and personalization. These cutting-edge technologies elucidate the intricate pathophysiological mechanisms and extensive heterogeneity inherent in diabetes， offering novel methodologies for early diagnosis， individualized treatment， and prognostic evaluation. This paradigm shift not only deepens the comprehension of diabetes complexity but also holds the potential to provide more precise and efficacious therapeutic interventions for patients. Consequently， this marks a historic transition from simplistic， clinically-based classification systems to sophisticated， molecular mechanism-based paradigms in diabetes classification.
| 1 | CHUNG W K， ERION K， FLOREZ J C，et al.Precision medicine in diabetes： a Consensus Report from the American Diabetes Association （ADA） and the European Association for the Study of Diabetes （EASD）［J］. Diabetologia，2020，63（9）：1671-1693. doi:10.1007/s00125-020-05181-w |
| 2 | ALBERTI K G， ZIMMET P Z.DEFINITION， diagnosis and classification of diabetes mellitus and its complications. Part 1： diagnosis and classification of diabetes mellitus provisional report of a WHO consultation［J］. Diabet Med，1998，15（7）：539-553. doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s |
| 3 | Organization W H.Classification of diabetes mellitus， 2019［M］. Geneva： WHO Document Production Services，2019. |
| 4 | 中国医师协会内分泌代谢科医师分会，国家代谢病临床研究中心. 糖尿病分型诊断中国专家共识［J］. 中华糖尿病杂志，2022，14（2）：120-139. doi:10.3760/cma.j.cn115791-20211219-00672 |
| 5 | 中华医学会糖尿病学分会，中华医学会内分泌学分会.中国1型糖尿病诊治指南（2021版）［J］. 中华糖尿病杂志， 2022，14（11）：1143-1250. |
| 6 | 中华医学会儿科学分会内分泌遗传代谢学组. 儿童单基因糖尿病临床诊断与治疗专家共识［J］. 中华儿科杂志，2019，57（7）：508-514. doi:10.3760/cma.j.issn.0578-1310.2019.07.003 |
| 7 | 中华医学会糖尿病学分会. 中国 2 型糖尿病防治指南（2020 年版）［J］. 中华糖尿病杂志， 2021，13（4）：315-409. |
| 8 | PETER P R， LUPSA B C. Personalized Management of Type 2 Diabetes［J］. Curr Diab Rep， 2019，19（11）：115. doi:10.1007/s11892-019-1244-0 |
| 9 | MISRA A， SATTAR N， TANDON N，et al. Clinical management of type 2 diabetes in south Asia［J］. Lancet Diabetes Endocrinol，2018，6（12）：979-991. doi:10.1016/s2213-8587(18)30199-2 |
| 10 | NAM S， CHESLA C， OTTS N A ST，et al. Barriers to diabetes management： patient and provider factors［J］. Diabetes Res Clin Pract，2011，93（1）：1-9. doi:10.1016/j.diabres.2011.02.002 |
| 11 | LAAKSO M.Biomarkers for type 2 diabetes［J］. Mol Metab，2019，27s（）：S139-S146. doi:10.1016/j.molmet.2019.06.016 |
| 12 | PHILIPSON L H. Harnessing heterogeneity in type 2 diabetes mellitus［J］. Nat Rev Endocrinol，2020，16（2）：79-80. doi:10.1038/s41574-019-0308-1 |
| 13 | KIM D S， GLOYN A L， KNOWLES J W. Genetics of Type 2 Diabetes： Opportunities for Precision Medicine： JACC Focus Seminar［J］. J Am Coll Cardiol，2021，78（5）：496-512. doi:10.1016/j.jacc.2021.03.346 |
| 14 | GLOYN A L， DRUCKER D J. Precision medicine in the management of type 2 diabetes［J］. Lancet Diabetes Endocrinol，2018，6（11）：891-900. doi:10.1016/s2213-8587(18)30052-4 |
| 15 | LANCET DIGITAL H THE. Equitable precision medicine for type 2 diabetes［J］. Lancet Digit Health，2022，4（12）：e850. doi:10.1016/s2589-7500(22)00217-5 |
| 16 | REUTENS A T. Diabetes： Individualized therapy for diabetes mellitus--just a promise？［J］. Nat Rev Endocrinol，2010，6（8）：426-427. doi:10.1038/nrendo.2010.88 |
| 17 | BLUESTONE J A， HEROLD K， Genetics EISENBARTH G.， pathogenesis and clinical interventions in type 1 diabetes［J］. Nature，2010，464（7293）：1293-1300. doi:10.1038/nature08933 |
| 18 | CARR A L J， EVANS-MOLINA C， ORAM R A. Precision medicine in type 1 diabetes［J］. Diabetologia，2022，65（11）：1854-1866. doi:10.1007/s00125-022-05778-3 |
| 19 | LYNAM A， MCDONALD T， HILL A，et al. Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years［J］. BMJ Open，2019，9（9）：e031586. doi:10.1136/bmjopen-2019-031586 |
| 20 | SHIELDS B M， PETERS J L， COOPER C，et al. Can clinical features be used to differentiate type 1 from type 2 diabetes？ A systematic review of the literature［J］. BMJ Open，2015，5（11）：e009088. doi:10.1136/bmjopen-2015-009088 |
| 21 | HOLT R I G， DEVRIES J H， HESS-FISCHL A，et al. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association （ADA） and the European Association for the Study of Diabetes （EASD）［J］. Diabetes Care，2021，44（11）：2589-2625. doi:10.2337/dci21-0043 |
| 22 | ACHENBACH P， HIPPICH M， ZAPARDIEL-GONZALO J，et al.A classification and regression tree analysis identifies subgroups of childhood type 1 diabetes［J］. EBioMedicine，2022，82：104118. doi:10.1016/j.ebiom.2022.104118 |
| 23 | LEETE P， ORAM R A， MCDONALD T J，et al. Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis［J］. Diabetologia，2020，63（6）：1258-1267. doi:10.1007/s00125-020-05115-6 |
| 24 | LEETE P， MORGAN N G. Footprints of Immune Cells in the Pancreas in Type 1 Diabetes； to "B" or Not to "B"： Is That Still the Question？［J］. Front Endocrinol （Lausanne），2021，12：617437. doi:10.3389/fendo.2021.617437 |
| 25 | LEETE P， WILLCOX A， KROGVOLD L，et al. Differential Insulitic Profiles Determine the Extent of β-Cell Destruction and the Age at Onset of Type 1 Diabetes［J］. Diabetes，2016，65（5）：1362-1369. doi:10.2337/db15-1615 |
| 26 | SMITH M J， CAMBIER J C， GOTTLIEB P A.Endotypes in T1D： B lymphocytes and early onset［J］. Curr Opin Endocrinol Diabetes Obes，2020，27（4）：225-230. doi:10.1097/med.0000000000000547 |
| 27 | NISHIMURA A， MATSUMURA K， KIKUNO S，et al. Slowly Progressive Type 1 Diabetes Mellitus： Current Knowledge And Future Perspectives［J］. Diabetes Metab Syndr Obes，2019，12：2461-2477. doi:10.2147/dmso.s191007 |
| 28 | MISHRA R， HODGE K M， COUSMINER D L，et al. A Global Perspective of Latent Autoimmune Diabetes in Adults［J］. Trends Endocrinol Metab，2018，29（9）：638-650. doi:10.1016/j.tem.2018.07.001 |
| 29 | COUSMINER D L， AHLQVIST E， MISHRA R，et al. First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes［J］. Diabetes Care，2018，41（11）：2396-2403. doi:10.2337/dc18-1032 |
| 30 | BUZZETTI R， TUOMI T， MAURICIO D，et al. Management of Latent Autoimmune Diabetes in Adults： A Consensus Statement From an International Expert Panel［J］. Diabetes，2020，69（10）：2037-2047. doi:10.2337/dbi20-0017 |
| 31 | AGARDH C D， LYNCH K F， PALMéR M，et al. GAD65 vaccination： 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes［J］. Diabetologia，2009，52（7）：1363-1368. doi:10.1007/s00125-009-1371-2 |
| 32 | DEUTSCH A J， AHLQVIST E， UDLER M S. Phenotypic and genetic classification of diabetes［J］. Diabetologia，2022，65（11）：1758-1769. doi:10.1007/s00125-022-05769-4 |
| 33 | THORENS B， RODRIGUEZ A， CRUCIANI-GUGLIELMACCI C，et al.Use of preclinical models to identify markers of type 2 diabetes susceptibility and novel regulators of insulin secretion-A step towards precision medicine［J］. Mol Metab，2019，27s（）：S147-s154. doi:10.1016/j.molmet.2019.06.008 |
| 34 | KAZE A D， SANTHANAM P， MUSANI S K，et al. Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus： Findings From the Look AHEAD Study［J］. J Am Heart Assoc，2021，10（7）：e016947. doi:10.1161/jaha.120.016947 |
| 35 | VALENSI P， AVIGNON A， SULTAN A，et al. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes： a cross-sectional study［J］. Cardiovasc Diabetol，2016，15（1）：104. doi:10.1186/s12933-016-0415-4 |
| 36 | SZCZERBINSKI L， FLOREZ J C. Precision medicine of obesity as an integral part of type 2 diabetes management - past， present， and future［J］. Lancet Diabetes Endocrinol，2023，11（11）：861-878. doi:10.1016/s2213-8587(23)00232-2 |
| 37 | FARAZ A， ASHRAF H， AHMAD J. Clinical Features， Biochemical Profile， and Response to Standard Treatment in Lean， Normal-Weight， and Overweight/Obese Indian Type 2 Diabetes Patients［J］. Rev Diabet Stud，2021，17（2）：68-74. doi:10.1900/rds.2021.17.68 |
| 38 | MOHAMMEDI K， CHALMERS J， HERRINGTON W，et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes［J］. Nutr Diabetes，2018，8（1）：7. doi:10.1038/s41387-017-0012-y |
| 39 | PARAMESWARAPPA D C， RAJALAKSHMI R， MOHAMED A，et al.Severity of diabetic retinopathy and its relationship with age at onset of diabetes mellitus in India： A multicentric study［J］. Indian J Ophthalmol，2021，69（11）：3255-3261. doi:10.4103/ijo.ijo_1459_21 |
| 40 | VAN HATEREN K J， LANDMAN G W， KLEEFSTRA N，et al.The lipid profile and mortality risk in elderly type 2 diabetic patients： a ten-year follow-up study （ZODIAC-13）［J］. PLoS One，2009，4（12）：e8464. doi:10.1371/journal.pone.0008464 |
| 41 | WYSHAM C， SHUBROOK J. Beta-cell failure in type 2 diabetes： mechanisms， markers， and clinical implications［J］. Postgrad Med，2020，132（8）：676-686. doi:10.1080/00325481.2020.1771047 |
| 42 | TAJIRI Y， KIMURA M， MIMURA K，et al. Variation of fasting serum C-peptide level after admission in Japanese patients with type 2 diabetes mellitus［J］. Diabetes Technol Ther，2009，11（9）：593-599. doi:10.1089/dia.2009.0010 |
| 43 | GUO Y， ZHAO X， LIU C Q，et al. A novel refined classification system for type 2 diabetes in adults： A Chinese retrospective cohort study［J］. Diabetes Metab Res Rev，2022，38（8）：e3577. doi:10.1002/dmrr.3577 |
| 44 | AHLQVIST E， STORM P， K?R?J?M?KI A，et al. Novel subgroups of adult-onset diabetes and their association with outcomes： a data-driven cluster analysis of six variables［J］. Lancet Diabetes Endocrinol，2018，6（5）：361-369. doi:10.1016/s2213-8587(18)30051-2 |
| 45 | MISRA S， WAGNER R， OZKAN B，et al. Precision subclassification of type 2 diabetes： a systematic review［J］. Commun Med （Lond），2023，3（1）：138. |
| 46 | IHARA K， SKUPIEN J， KOBAYASHI H，et al. Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria［J］.Diabetes Care，2020，43（11）：2760-2767. doi:10.2337/dc20-0630 |
| 47 | LINNEMANN B， VOIGT W， NOBEL W，et al. C-reactive protein is a strong independent predictor of death in type 2 diabetes： association with multiple facets of the metabolic syndrome［J］.Exp Clin Endocrinol Diabetes，2006，114（3）：127-134. doi:10.1055/s-2006-924012 |
| 48 | JIAN W， PENG W， XIAO S，et al. Role of serum vaspin in progression of type 2 diabetes： a 2-year cohort study［J］. PLoS One，2014，9（4）：e94763. doi:10.1371/journal.pone.0094763 |
| 49 | GONG S， GUO J， HAN X，et al. Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria［J］. J Clin Endocrinol Metab， 2017，102（5）：1548-1556. doi:10.1210/jc.2016-2332 |
| 50 | SALEEM T， DAHPY M， EZZAT G，et al. The Profile of Plasma Free Amino Acids in Type 2 Diabetes Mellitus with Insulin Resistance： Association with Microalbuminuria and Macroalbuminuria［J］. Appl Biochem Biotechnol，2019，188（3）：854-867. doi:10.1007/s12010-019-02956-9 |
| 51 | USMAN M， KHUNTI K， DAVIES M J，et al. Association and relative importance of multiple risk factor control on cardiovascular disease， end-stage renal disease and mortality in people with type 2 diabetes： A population-based retrospective cohort study［J］. Prim Care Diabetes，2021，15（2）：218-226. doi:10.1016/j.pcd.2020.08.008 |
| 52 | FENG X， ZHAI G， YANG J，et al. Myocardial Infarction and Coronary Artery Disease in Menopausal Women With Type 2 Diabetes Mellitus Negatively Correlate With Total Serum Bile Acids［J］. Front Endocrinol （Lausanne），2021，12：754006. doi:10.3389/fendo.2021.754006 |
| 53 | WARREN R A， CAREW A S， ANDREOU P，et al. Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event： ACCORD Lipid Trial［J］. Diabetes Care，2022，45（1）：241-250. doi:10.2337/dc21-1429 |
| 54 | YU H， WANG H， SU X，et al. Serum chromogranin A correlated with albuminuria in diabetic patients and is associated with early diabetic nephropathy［J］. BMC Nephrol，2022，23（1）：41. doi:10.1186/s12882-022-02667-0 |
| 55 | ZAHARIA O P， STRASSBURGER K， STROM A，et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes： a 5-year follow-up study［J］. Lancet Diabetes Endocrinol，2019，7（9）：684-694. doi:10.1016/s2213-8587(19)30187-1 |
| 56 | LANDGRAF W， OWENS D R， FRIER B M，et al. Treatment responses to basal insulin glargine 300?U/ml and glargine 100?U/ml in newly defined subphenotypes of type 2 diabetes： A post hoc analysis of the EDITION 3 randomized clinical trial［J］. Diabetes Obes Metab，2024，26（2）：503-511. |
| 57 | DENNIS J M， SHIELDS B M， HENLEY W E，et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features： an analysis using clinical trial data［J］. Lancet Diabetes Endocrinol，2019，7（6）：442-451. doi:10.1016/s2213-8587(19)30087-7 |
| 58 | MANSOUR ALY D， DWIVEDI O P， PRASAD R B，et al.Genome-wide association analyses highlight etiological differences underlying newly defined subtypes of diabetes［J］. Nat Genet，2021，53（11）：1534-1542. doi:10.1038/s41588-021-00948-2 |
| 59 | ZAGHLOOL S B， HALAMA A， STEPHAN N，et al. Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population［J］. Nat Commun，2022，13（1）：7121. doi:10.1038/s41467-022-34754-z |
| 60 | LUGNER M， GUDBJ?RNSDOTTIR S， SATTAR N，et al. Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes： nationwide observational study［J］. Diabetologia，2021，64（9）：1973-1981. doi:10.1007/s00125-021-05485-5 |
| 61 | BELLO-CHAVOLLA O Y， BAHENA-LóPEZ J P， VARGAS-VáZQUEZ A，et al. Clinical characterization of data-driven diabetes subgroups in Mexicans using a reproducible machine learning approach［J］. BMJ Open Diabetes Res Care，2020，8（1）：e001550. doi:10.1136/bmjdrc-2020-001550 |
| 62 | WANG F， ZHENG R， LI L，et al. Novel Subgroups and Chronic Complications of Diabetes in Middle-Aged and Elderly Chinese：A Prospective Cohort Study［J］. Front Endocrinol （Lausanne），2021，12：802114. doi:10.3389/fendo.2021.802114 |
| 63 | LI L， CHENG W Y， GLICKSBERG B S，et al. Identification of type 2 diabetes subgroups through topological analysis of patient similarity［J］. Sci Transl Med，2015，7（311）：311ra174. doi:10.1126/scitranslmed.aaa9364 |
| 64 | SENG J J B， KWAN Y H， LEE V S Y，et al. Differential Health Care Use， Diabetes-Related Complications， and Mortality Among Five Unique Classes of Patients With Type 2 Diabetes in Singapore： A Latent Class Analysis of 71，125 Patients［J］. Diabetes Care，2020，43（5）：1048-1056. doi:10.2337/dc19-2519 |
| 65 | MARIAM A， MILLER-ATKINS G， PANTALONE K M，et al. A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment［J］. Diabetes Care，2021，44（6）：1410-1418. doi:10.2337/dc20-2700 |
| 66 | BANCKS M P， CHEN H， BALASUBRAMANYAM A，et al. Type 2 Diabetes Subgroups， Risk for Complications， and Differential Effects Due to an Intensive Lifestyle Intervention［J］. Diabetes Care，2021，44（5）：1203-1210. doi:10.2337/dc20-2372 |
| 67 | BASU S， RAGHAVAN S， WEXLER D J，et al. Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk： Machine Learning Analysis of the ACCORD Trial［J］. Diabetes Care，2018，41（3）：604-612. doi:10.2337/dc17-2252 |
| 68 | SHARMA A， ZHENG Y， EZEKOWITZ J A，et al. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease： A Potential Approach to Precision Medicine［J］. Diabetes Care，2022，45（1）：204-212. doi:10.2337/dc20-2806 |
| 69 | KARPATI T， LEVENTER-ROBERTS M， FELDMAN B，et al. Patient clusters based on HbA1c trajectories： A step toward individualized medicine in type 2 diabetes［J］. PLoS One，2018，13（11）：e0207096. doi:10.1371/journal.pone.0207096 |
| 70 | LIN C C， LI C I， LIU C S，et al. Three-year trajectories of metabolic risk factors predict subsequent long-term mortality in patients with type 2 diabetes［J］. Diabetes Res Clin Pract，2021，179：108995. doi:10.1016/j.diabres.2021.108995 |
| 71 | WESOLOWSKA-ANDERSEN A， BRORSSON C A， BIZZOTTO R，et al. Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals： An IMI DIRECT study［J］. Cell Rep Med，2022，3（1）：100477. doi:10.1016/j.xcrm.2021.100477 |
| 72 | NAIR A T N， WESOLOWSKA-ANDERSEN A， BRORSSON C，et al. Heterogeneity in phenotype， disease progression and drug response in type 2 diabetes［J］. Nat Med，2022，28（5）：982-988. doi:10.1038/s41591-022-01790-7 |
/
| 〈 |
|
〉 |